Pharmacological targeting MER with an ATP-competitive inhibitor of TAM receptors MRX-2843 shifted the balance of macrophage polarisation from M2 to M1 and stimulated anti-tumour immune response in a mouse orthotopic model of glioblastoma [64]. Here, MERTK is linked to neoplasm.